Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Novo Nordisk A/S — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Novo Nordisk A/S trades at $37.81 (market cap $169.08B). The key difference: Novo Nordisk A/S is far larger — about 5.4× GE HealthCare Technologies Inc. Common Stock's market cap, and Novo Nordisk A/S pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| GEHC | NVO | |
|---|---|---|
Market Cap | $31.07B | $169.08B |
Volume | 3,443,020 | 9,259,152 |
Sector | Health | Health |
52-Week High | $88.16 | $63.98 |
52-Week Low | $59.48 | $35.29 |
Enterprise Value | $39.53B | $183.28B |
Dividend Yield | 0.23% | 4.72% |
Typical Hold Time | — | 116 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Novo Nordisk (NVO) trades at $38.12, down 1.19% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.96, beating expectations by 17%, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 9.67 and ROE of 59.82%, while recent news highlights pipeline expansion through $4 billion in licensing deals and progress on oral Wegovy formulations.
The stock presents a compelling value opportunity with strong profitability and growth prospects in obesity/diabetes markets, though technical weakness and competitive pressure from Eli Lilly create near-term headwinds. Analyst consensus remains bullish with $42.33 price target representing 11% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
